Zhi Tong Cai Jing·2026-01-14 10:10Group 1 - The core announcement is that Fosun Pharma's subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has had its drug registration application for injectable lactulose erythromycin accepted by the National Medical Products Administration [1] - The drug is intended for use when oral administration is not feasible or when a rapid high serum concentration of erythromycin is required for treating infections caused by specific sensitive microbial strains, as well as for preventing rheumatic fever and bacterial endocarditis [1] - As of December 2025, the cumulative R&D investment for this drug by the group is approximately RMB 6.33 million (unaudited) [1] Group 2 - According to the latest data from IQVIA CHPA, the sales revenue for injectable lactulose erythromycin in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be approximately RMB 170 million in 2024 [1]